COMP <GO>
RMTI vs NXTC // EV/EBITDA & P/E VALUATION
Rockwell Medical Inc. (NASDAQ) VS. NextCure Inc. (NASDAQ) • 15-METRIC TALLY: RMTI 2
— NXTC 2
■ METRIC PARITY
LAST: $7.31 (0.00%) • MKT CAP: $29.5M
valuation
—
LAST: $6.53 (+2.92%) • MKT CAP: $29.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RMTI VS. NXTC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RMTI | NXTC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 16.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.60% | -35.00% | +24.40 | RMTI | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -6.80% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -7.70% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | RMTI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.0 | 54.3 | -13.30 | NXTC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.5M | $29.9M | -$404.6K | NXTC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RMTI REV | NXTC REV | RMTI GROSS % | NXTC GROSS % | RMTI FCF | NXTC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $69.3M | $0 | 16.9% | — | -$659.0K | -$49.6M |
| FY 2024 | $101.5M | $0 | 17.2% | — | $4.2M | -$41.3M |
| FY 2023 | $0 | $0 | — | — | -$9.4M | -$53.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RMTI // BETA —
NXTC // BETA —